Suppr超能文献

间充质干细胞来源的外泌体在乳腺癌中诱导髓系细胞向免疫抑制型 M2 极化的巨噬细胞分化。

Exosomes Produced by Mesenchymal Stem Cells Drive Differentiation of Myeloid Cells into Immunosuppressive M2-Polarized Macrophages in Breast Cancer.

机构信息

Immunology Laboratory, Department of Zoology, University of Calcutta, Kolkata 700019, India.

Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612.

出版信息

J Immunol. 2019 Dec 15;203(12):3447-3460. doi: 10.4049/jimmunol.1900692. Epub 2019 Nov 8.

Abstract

Tumor-associated macrophages are major contributors to malignant progression and resistance to immunotherapy, but the mechanisms governing their differentiation from immature myeloid precursors remain incompletely understood. In this study, we demonstrate that exosomes secreted by human and mouse tumor-educated mesenchymal stem cells (MSCs) drive accelerated breast cancer progression by inducing differentiation of monocytic myeloid-derived suppressor cells into highly immunosuppressive M2-polarized macrophages at tumor beds. Mechanistically, MSC-derived exosomes but not exosomes from tumor cells contain TGF-β, C1q, and semaphorins, which promote myeloid tolerogenic activity by driving PD-L1 overexpression in both immature myelomonocytic precursors and committed CD206 macrophages and by inducing differentiation of MHC class II macrophages with enhanced l-Arginase activity and IL-10 secretion at tumor beds. Accordingly, administration of tumor-associated murine MSC-derived exosomes accelerates tumor growth by dampening antitumor immunity, and macrophage depletion eliminates exosome-dependent differences in malignant progression. Our results unveil a new role for MSC-derived exosomes in the differentiation of myeloid-derived suppressor cells into macrophages, which governs malignant growth.

摘要

肿瘤相关巨噬细胞是恶性进展和免疫治疗耐药的主要贡献者,但调节其从未成熟髓样前体分化的机制仍不完全清楚。在这项研究中,我们证明了人类和小鼠肿瘤诱导的间充质干细胞(MSC)分泌的外泌体通过诱导单核细胞髓样来源的抑制细胞分化为高度免疫抑制的 M2 极化巨噬细胞,在肿瘤部位加速乳腺癌的进展。从机制上讲,MSC 衍生的外泌体而不是肿瘤细胞衍生的外泌体含有 TGF-β、C1q 和 semaphorins,通过在未成熟的髓样单核前体和已分化的 CD206 巨噬细胞中过表达 PD-L1,并通过诱导 MHC 类 II 巨噬细胞分化,增强 l-精氨酸酶活性和 IL-10 分泌,在肿瘤部位发挥髓样耐受活性。因此,肿瘤相关的鼠 MSC 衍生的外泌体的给药通过抑制抗肿瘤免疫来加速肿瘤生长,而巨噬细胞耗竭消除了恶性进展中外泌体依赖性差异。我们的结果揭示了 MSC 衍生的外泌体在髓样来源的抑制细胞向巨噬细胞分化中的新作用,从而控制恶性生长。

相似文献

5
Lung Tumor Cell-Derived Exosomes Promote M2 Macrophage Polarization.
Cells. 2020 May 24;9(5):1303. doi: 10.3390/cells9051303.
6
Breast Cancer-Derived Exosomes Alter Macrophage Polarization gp130/STAT3 Signaling.
Front Immunol. 2018 May 8;9:871. doi: 10.3389/fimmu.2018.00871. eCollection 2018.
7

引用本文的文献

1
Revolutionizing cancer treatment: engineering mesenchymal stem cell-derived small extracellular vesicles.
Cancer Cell Int. 2025 Jul 21;25(1):275. doi: 10.1186/s12935-025-03900-0.
2
Tumor-associated mesenchymal stem/stromal cells in tumor microenvironment and carcinogenesis.
Exp Hematol Oncol. 2025 Jul 17;14(1):97. doi: 10.1186/s40164-025-00688-7.
8
Extracellular vesicles and miRNA-based therapies in triple-negative breast cancer: advances and clinical perspectives.
Extracell Vesicles Circ Nucl Acids. 2025 Feb 14;6(1):54-71. doi: 10.20517/evcna.2024.85. eCollection 2025.
9
Histone acetylation modulators in breast cancer.
Breast Cancer Res. 2025 Mar 31;27(1):49. doi: 10.1186/s13058-025-02006-9.
10
Immunomodulatory effects and clinical application of exosomes derived from mesenchymal stem cells.
World J Stem Cells. 2025 Mar 26;17(3):103560. doi: 10.4252/wjsc.v17.i3.103560.

本文引用的文献

1
Effect of mesenchymal stem cells-derived exosomes on tumor microenvironment: Tumor progression versus tumor suppression.
J Cell Physiol. 2019 Apr;234(4):3394-3409. doi: 10.1002/jcp.27326. Epub 2018 Oct 26.
2
Ovarian Carcinoma-Associated Mesenchymal Stem Cells Arise from Tissue-Specific Normal Stroma.
Stem Cells. 2019 Feb;37(2):257-269. doi: 10.1002/stem.2932. Epub 2018 Nov 2.
3
Plasticity of myeloid-derived suppressor cells in cancer.
Curr Opin Immunol. 2018 Apr;51:76-82. doi: 10.1016/j.coi.2018.03.009. Epub 2018 Mar 14.
4
Heterodimer formation by Oct4 and Smad3 differentially regulates epithelial-to-mesenchymal transition-associated factors in breast cancer progression.
Biochim Biophys Acta Mol Basis Dis. 2018 Jun;1864(6 Pt A):2053-2066. doi: 10.1016/j.bbadis.2018.03.010. Epub 2018 Mar 8.
5
Mesenchymal-myeloid interaction in the regulation of immunity.
Semin Immunol. 2018 Feb;35:59-68. doi: 10.1016/j.smim.2018.01.002. Epub 2018 Feb 1.
6
Immune modulation by a cellular network of mesenchymal stem cells and breast cancer cell subsets: Implication for cancer therapy.
Cell Immunol. 2018 Apr;326:33-41. doi: 10.1016/j.cellimm.2017.07.011. Epub 2017 Aug 1.
7
SATB1 Expression Governs Epigenetic Repression of PD-1 in Tumor-Reactive T Cells.
Immunity. 2017 Jan 17;46(1):51-64. doi: 10.1016/j.immuni.2016.12.015.
8
The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression.
Vaccines (Basel). 2016 Nov 3;4(4):36. doi: 10.3390/vaccines4040036.
9
Trametinib Drives T-cell-Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis.
Cancer Res. 2016 Nov 1;76(21):6253-6265. doi: 10.1158/0008-5472.CAN-16-1308.
10
Recent discoveries concerning the tumor - mesenchymal stem cell interactions.
Biochim Biophys Acta. 2016 Dec;1866(2):290-299. doi: 10.1016/j.bbcan.2016.10.004. Epub 2016 Oct 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验